CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CNBX Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.61B shares outstanding
USCNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers.
Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer.
The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022.
It operates as a subsidiary of Cannabics Inc.
Leadership
Gabriel Yariv
President, Chief Operating Officer & Executive Chairman
Eyal Barad
Co-Founder, Chief Executive Officer & Director
Uri Ben-Or
Chief Financial Officer
Ilya Reznik
Head of Neuropsychiatry Development
Employees
1
Country
US
Sector
Healthcare
Website
cnbxpharma.com
| Name | Shares | % | Source |
|---|---|---|---|
3i, LP · joint filing· may incl. warrants· filed May 2026 | 124.9M | 7.8% | 13G |
based on 1.61B shares outstanding
US30d Avg
12.13M
60d Avg
8.88M
90d Avg
6.41M